DrugPatentWatch Database Preview
Details for Patent: 6,258,795
Which drugs does patent 6,258,795 protect, and when does it expire?
Patent 6,258,795 protects VISTOGARD and XURIDEN and is included in two NDAs.
This patent has one hundred and seventy-two patent family members in twenty-one countries.
This patent has one hundred and seventy-two patent family members in twenty-one countries.
Summary for Patent: 6,258,795
| Title: | Acylated uridine and cytidine and uses thereof |
| Abstract: | The invention relates to compositions comprising acyl derivatives of cytidine and uridine. The invention also relates to methods of treating hepatopathies, diabetes, heart disease, cerebrovascular disorders, Parkinson's disease, infant respiratory distress syndrome and for enhancement of phospholipid biosynthesis comprising administering the acyl derivatives of the invention to an animal. |
| Inventor(s): | von Borstel; Reid Warren (Darnestown, MD), Bamat; Michael Kevin (Darnestown, MD) |
| Assignee: | Pro-Neuron, Inc. (Gaithersburg, MD) |
| Application Number: | 08/466,145 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 6,258,795
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wellstat Therap | VISTOGARD | uridine triacetate | GRANULE;ORAL | 208159-001 | Dec 11, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||||
| Wellstat Therap | XURIDEN | uridine triacetate | GRANULE;ORAL | 208169-001 | Sep 4, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 6,258,795
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 5,583,117 | Acylated uridine and cytidine for elevating tissue uridine and cytidine | ➤ Sign Up |
| 5,691,320 | Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis | ➤ Sign Up |
| 6,329,350 | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | ➤ Sign Up |
| 5,736,531 | Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 6,258,795
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Russian Federation | 2158269 | ➤ Sign Up | |||
| Russian Federation | 2115410 | ➤ Sign Up | |||
| Portugal | 1491201 | ➤ Sign Up | |||
| Portugal | 679160 | ➤ Sign Up | |||
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
